Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
0.7398
-0.0138 (-1.83%)
At close: Nov 21, 2025, 4:00 PM EST
0.7398
0.00 (0.00%)
Pre-market: Nov 24, 2025, 8:01 AM EST
Biofrontera Employees
As of December 31, 2024, Biofrontera had 93 total employees, including 92 full-time and 1 part-time employees. The number of employees increased by 8 or 9.41% compared to the previous year.
Employees
93
Change (1Y)
8
Growth (1Y)
9.41%
Revenue / Employee
$399,613
Profits / Employee
-$188,946
Market Cap
8.62M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 93 | 8 | 9.41% |
| Dec 31, 2023 | 85 | 4 | 4.94% |
| Dec 31, 2022 | 81 | 12 | 17.39% |
| Dec 31, 2021 | 69 | 13 | 23.21% |
| Dec 31, 2020 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BFRI News
- 10 days ago - Biofrontera Inc. (BFRI) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 17 days ago - Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M - GlobeNewsWire
- 17 days ago - Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025 - GlobeNewsWire
- 4 weeks ago - Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG - GlobeNewsWire
- 2 months ago - Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - GlobeNewsWire
- 2 months ago - Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program - GlobeNewsWire
- 2 months ago - Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk - GlobeNewsWire